pyrazines has been researched along with Acute Lymphoid Leukemia in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (24.24) | 29.6817 |
| 2010's | 22 (66.67) | 24.3611 |
| 2020's | 3 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Barnett, K; Crews, K; Diedrich, JD; Huang, X; Konopleva, M; Li, Z; Pui, CH; Reyes, N; Savic, D; Smart, B; Wang, P; Wei, CL; Xu, B; Yang, JJ; Yang, W; Yeoh, AEJ; Yoshimura, S; Yu, J; Zhang, J; Zhao, X | 1 |
| Bagashev, A; Brown, PA; Loftus, JP; Niswander, LM; Schauf, A; Tannheimer, S; Tasian, SK; Wang, M; Yahiaoui, A | 1 |
| Ebadi, M; Gordon, DJ; Gordon, PM; Jonart, LM; Koppenhafer, SL; Ostergaard, J | 1 |
| Bostrom, BC; Messinger, YH | 1 |
| Coelho-Silva, JL; Fenerich, BA; Fernandes, JC; Machado-Neto, JA; Rego, EM; Ridley, AJ; Rodrigues Alves, APN; Scheucher, PS; Simões, BP; Traina, F | 1 |
| Anderl, J; Assaraf, YG; Cloos, J; de Haas, V; Degenhardt, J; Franke, NE; Horton, TM; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; Schimmer, AD; van Meerloo, J; Zweegman, S | 1 |
| Ashikaga, T; Keino, D; Kinoshita, A; Kondoh, K; Morimoto, M; Ohyama, R; Yamashita, A | 1 |
| Cashen, A; Cheng, EH; DiPersio, J; Hsieh, JJ; Kunkle, L; Liu, H; Pham, CG; Piwnica-Worms, DR; Vij, R; Westergard, TD | 1 |
| Güngör, T; Waespe, N; Zeilhofer, U | 1 |
| Imai, K | 1 |
| Chen, HX; Wang, XJ; Xu, YH; Yang, GC; Zhang, P | 1 |
| da Silva, FB; Fenerich, BA; Fernandes, JC; Machado-Neto, JA; Rego, EM; Rodrigues Alves, APN; Scopim-Ribeiro, R; Simões, BP; Traina, F | 1 |
| Gaynon, PS | 1 |
| Chen, L; Chen, Z; Gong, S; Guo, L; Lü, S; Wang, J; Yang, J; Zhou, H | 1 |
| Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N | 1 |
| Chou, T; Hirose, T; Igarashi, N; Imai, Y; Ishiguro, T; Nemoto, K | 1 |
| Bostrom, BC; Dubois, S; Eckroth, E; Gaynon, P; Glade-Bender, J; Hutchinson, R; Messinger, Y; Raetz, E; Sposto, R; van der Giessen, J | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
| Gong, YP; Yang, X; Zheng, BH; Zhou, RQ | 1 |
| Chang, H; Gong, YP; Xing, HY; Yang, L; Yang, X; Zheng, BH; Zhou, RQ | 1 |
| Claxton, DF | 1 |
| Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Wang, L | 1 |
| Hu, XH; Shen, YY; Xu, JJ | 1 |
| Bigley, V; Collin, M; Hambleton, S; Jardine, L; Pagan, S; Wang, XN | 1 |
| Borst, J; Rooswinkel, RW; van de Kooij, B; Verheij, M | 1 |
| Ceder, R; Fadeel, B; Grafström, RC; Grandér, D; Hedenfalk, I; Heyman, M; Ottosson-Wadlund, A; Pokrovskaja, K; Preta, G; Robertson, JD; Söderhäll, S | 1 |
| Chen, Q; Du, XL | 1 |
| Bastian, L; Eckert, C; Fichtner, I; Henze, G; Hof, J; Pfau, M; Prada, J; Seeger, K; Shalapour, S; von Stackelberg, A | 1 |
| Kato, M; Kimura, H; Kobayashi, Y; Kozawa, K; Kuroiwa, M; Minakami, H; Morikawa, A; Oshima, S | 1 |
| Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Guerciolini, R; Kantarjian, H; Koller, C; McConkey, D; Patel, G; Ruiz, SL; Thomas, D; Wright, J | 1 |
| Bostrom, B; Brown, RE; Zhang, PL | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Carol, H; Houghton, PJ; Keir, ST; Keshelava, N; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Wu, J | 1 |
4 review(s) available for pyrazines and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
[Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Octreotide; Pancreatitis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Treatment Outcome; Vincristine | 2014 |
[Treatment of adult Ph-negative acute lymphoblastic leukemia].
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Combined Modality Therapy; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Transplantation Conditioning; Young Adult | 2014 |
Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Thrombocytopenia; Valproic Acid | 2013 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
4 trial(s) available for pyrazines and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Boronic Acids; Bortezomib; Child; Child, Preschool; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protease Inhibitors; Pyrazines; Salvage Therapy; Treatment Outcome; Vincristine | 2010 |
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Drug Synergism; Female; Histone Deacetylase 6; Histone Deacetylases; HL-60 Cells; Humans; Hydroxamic Acids; I-kappa B Kinase; Jurkat Cells; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Pyrazines; Signal Transduction; Sulfonamides; Transcription Factor RelA; Tubulin; U937 Cells; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recurrence; Time Factors | 2004 |
25 other study(ies) available for pyrazines and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.
Topics: Aniline Compounds; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Gene Fusion; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Trans-Activators; Transcription Factors | 2022 |
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Topics: Animals; Heterografts; Humans; Indazoles; Infant; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines | 2021 |
Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2021 |
Bortezomib Comes to the Rescue: Comment on the Article by Nachmias et al. Entitled "A Bortezomib-Based Protocol Induces a High Rate of CR with Minor Toxicity in Adult Patients with Relapsed/Refractory ALL".
Topics: Adult; Boronic Acids; Bortezomib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Remission Induction | 2018 |
IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Humans; Imidazoles; Insulin Receptor Substrate Proteins; Jurkat Cells; Middle Aged; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyrogallol; Receptor, IGF Type 1; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Young Adult | 2019 |
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines | 2013 |
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Topics: Adult; Animals; Apoptosis; Boronic Acids; Bortezomib; DNA-Binding Proteins; G2 Phase Cell Cycle Checkpoints; Histone-Lysine N-Methyltransferase; Humans; M Phase Cell Cycle Checkpoints; Mice; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Transcriptional Elongation Factors; Transfection; Translocation, Genetic | 2014 |
Treatment-refractory multi-lineage autoimmune cytopenia after unrelated cord blood transplantation: remission after combined bortezomib and vincristine treatment.
Topics: Boronic Acids; Bortezomib; Cord Blood Stem Cell Transplantation; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Infant; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Purpura, Thrombocytopenic, Idiopathic; Pyrazines; Vincristine | 2014 |
Tetramethylpyrazine inhibits the proliferation of acute lymphocytic leukemia cell lines via decrease in GSK-3β.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Inhibitor of Apoptosis Proteins; Jurkat Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survivin; Transcription Factor RelA | 2015 |
IRS1/β-Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells.
Topics: Active Transport, Cell Nucleus; Adolescent; Adult; beta Catenin; Blotting, Western; Humans; Imidazoles; Immunoprecipitation; Insulin Receptor Substrate Proteins; Microscopy, Confocal; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-myc; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin; RNA, Messenger; Signal Transduction; Young Adult | 2017 |
"The Second Time is Sweeter After All".
Topics: Boronic Acids; Bortezomib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines | 2017 |
Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Survival; Chymotrypsin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; K562 Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2008 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2009 |
Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tissue Donors; Transplantation, Homologous | 2009 |
[Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tumor Cells, Cultured; Young Adult | 2010 |
[The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Daunorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyrimidines | 2010 |
Out foxing bcr-abl.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2011 |
[Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Treatment Outcome | 2011 |
Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.
Topics: Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Chromans; Humans; Killer Cells, Natural; Ligands; NK Cell Lectin-Like Receptor Subfamily K; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Thiazolidinediones; Troglitazone; Up-Regulation; Valproic Acid | 2013 |
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; T-Lymphocytes; Tumor Suppressor Protein p53 | 2012 |
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
Topics: Adolescent; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Boronic Acids; Bortezomib; Caspase 3; Child; Child, Preschool; Cytochromes c; fas Receptor; Fas-Associated Death Domain Protein; Gene Silencing; Humans; Jurkat Cells; Leukemia, Myeloid; Membrane Potential, Mitochondrial; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transcriptome | 2013 |
Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Leukemia, B-Cell; Mice; NF-kappa B; Phosphatidylinositol 3-Kinases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Pyrazines; Transcription Factor RelA; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Superoxide radical generation and Mn- and Cu-Zn superoxide dismutases activities in human leukemic cells.
Topics: Adult; Anions; Child; Humans; Imidazoles; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukocytes; Manganese; Monocytes; N-Formylmethionine Leucyl-Phenylalanine; Oxidative Stress; Oxygen; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Sodium Dodecyl Sulfate; Superoxide Dismutase; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 2003 |
Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; B-Lymphocytes; Boronic Acids; Bortezomib; Child; Dexamethasone; Humans; Male; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence | 2004 |
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Mice; Mice, Inbred Strains; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protease Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2008 |